anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses application of macrophages induced by ISG15 and ISG15 and secretion thereof in tumor treatment, and the research of the invention shows that the macrophages induced by ISG15 are in an M2-like phenotype, and the migration and the tumorigenicity of nasopharyngeal carcinoma cells are enhanced. And the M2-like phenotype induced by ISG15 was associated with the interaction of ISG15 with the ISG15 receptor LFA-1, the involvement of SRC Family Kinase (SFK) signaling, and the subsequent secretion of CCL 18. Blockade of LFA-1 or SRC signaling by small molecule inhibitors, or neutralization by anti-ccl 18 antibodies, inhibited activation of the LFA-1-sfk-ccl18 pathway in isg15-treated macrophages. In clinic, the medicine is prepared by the steps of,ISG15 + CD163 + TAMs are related to the survival impairment of patients and the advanced tumor stage of nasopharyngeal carcinoma. Also, ISG15 was found + CD163 + Macrophages suppress the response of anti-tumor CD8+ cells in nasopharyngeal carcinoma. That is, ISG15 secreted by tumor cells acts as a tumor microenvironment factor, can induce an M2-like phenotype, promote tumor progression and suppress cytotoxic T lymphocyte responses. Therefore, the invention provides the application of the secretion of the macrophages processed by ISG15, ISG15 and ISG15 in tumor treatment.
Mesenchymal Stem Cells (MSCs) have been shown to have immunosuppressive and repairing properties. Bone marrow mononuclear cells (BMMNCs) have revascularization properties and complimentary effects to MSCs. Patients in this study will receive infusion of expanded autologous MSC and BMMNCs. The puncture of femoral artery will be conducted with digital subtraction angiography(DSA), and the tubes will be inserted into medial femoral circumflex artery,lateral femoral circumflex artery and obturatou artey. The study will evaluate the safety and effectiveness of MSC infusion in patients with osteonecrosis of the femoral head. This study will last for 5 years. Patients will undergo infusions at Day 0. Afterward, patients will be evaluated for response, and undergo X-ray examination, CT and MR scanning at a 6-month interval.
Saline solution (NaCl 0.9%), B. Braun Ecoflac® Plus 50mL. One single administration intramuscularly of a 1.0mL dose on Day 1.
PROBLEM TO BE SOLVED: To obtain a new compound useful as an intermediate for producing compounds having anti-carcinogenesis promoter activity and cerebral nerve cell death inhibitory action and the like. SOLUTION: This new compound is a compound shown by formura I [R1, R3 and R4 are each a lower alkyl; R2 is a lower alkyl, aralkyl or (substituted) aryl], e.g. 4-hydroxyimino-5,6-dimethoxy-6-methyl-2-pentylperhydro-3H-pyran-3- one. The compound of formula I is obtained by reacting a compound of formula II (e.g. 6-methoxy-6-methyl-2-pentyl-2,6-dihydro-3H-pyran-3-one) with a compound of the formura: R4OH (e.g. methanol) and a nitrous acid compound such as sodium nitrite in a solvent such as hydrochloric acid-methanol solution, pref. at -20 to 50 deg.C for 1-10 h. This compound is useful as an intermediate for producing 2,6-dialkyl-y-pyrone derivatives.
Cancer-associated venous thromboembolism (CAT) is common in patients with cancer and associated with significant morbidity and mortality. The incidence of CAT continues to rise, complicating patient care and burdening healthcare systems. Patients with cancer experiencing VTE face poorer prognoses, making prevention and effective management imperative. This narrative review synthesizes evidence on thromboprophylaxis in ambulatory patients with cancer receiving systemic therapy and acute treatment strategies for CAT. Risk assessment models (e.g., Khorana score) aid in identifying high-risk patients who may benefit from thromboprophylaxis. Pharmacological thromboprophylaxis with low molecular weight heparins (LMWHs) and direct oral anticoagulants (DOACs) has been shown to reduce the risk of CAT without significantly increasing the risk of bleeding complications. However, implementation of risk-based strategies remains limited in clinical practice. For acute CAT management, LMWHs have been the standard of care, but DOACs are increasingly favored due to their convenience and efficacy. However, challenges persist, including bleeding risks and drug interactions. Emerging therapies targeting Factor XI inhibitors present promising alternatives, potentially addressing current limitations in anticoagulation management for CAT.
A 5-module program based on motivational interviewing (MI) and cognitive behavioral therapy (CBT) is tested among help-seekers at one outpatient clinic within the Stockholm Center for Dependency Disorders: Riddargatan 1.The design is a two-armed randomized controlled non-inferiority study, and outcomes are measured in terms of changes in alcohol consumption, problematic alcohol use, alcohol dependence alcohol use disorder, anxiety, as well as depression and quality of life. 600 participants are recruited online from the clinic's website. Consenting participants will complete baseline questionnaires online and participate in face-to-face assessment by a physician at the clinic. Eligible individuals will then be randomized into one of two groups: 1.Internet-based treatment program with online counselor support. 2. Face-to-face treatment with 5 individual counselor sessions at the clinic. Follow-up will be conducted online after 3, 6, 12 and 24 months in both groups.
Based on standard medical care, after evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a combination therapy of a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules, including 3 gram of Huangqi(Astragalus root), 2 gram of Renshen(ginseng), 2.5 gram of Danggui(Angelica sinensis), 2 gram of Danshen(Salvia miltiorrhiza), 2 gram of Dilong(Geosaurus), 3 gram of Chishao(Radix Paeoniae Rubra), 2 gram of Honghua(Safflower), 2 gram of Chuanxiong(Rhizoma Chuanxiong), 2 gram of Sanqi(Radix Notoginseng), 3 gram of Shudihuang(Radix Rehmanniae Preparata). The Chinese herbal granule formula could be weekly changed according to differentiation of Zhenghou.
During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
BACKGROUND: Cervical cancer screening results that are negative for cytology but positive for high-risk human papillomavirus (HR-HPV) are not uncommon. One-year follow-up is suggested for patients with no history of HPV positivity under the most recent American Society of Colposcopy and Cervical Pathology (ASCCP) guidelines (2019). The aim of this study was to evaluate the immediate risk of cervical intraepithelial neoplasia (CIN) among cytology-negative patients positive for HR-HPV. The diagnostic accuracy of colposcopy in these patients was investigated.
METHODS: A retrospective study was conducted in patients who were cytology negative but HR-HPV positive and referred for colposcopy from January 2022 to August 2023. Patients were compared in terms of the immediate rate of CIN lesions among the HPV16-positive group, the HPV18-positive group and the non-16/18 HR-HPV-positive group. The distribution of CIN2 + lesions according to age was evaluated. The factors associated with the accuracy of colposcopy were evaluated using univariate and multivariate logistic regression.
RESULTS: Among the 372 patients, 195 had chronic cervicitis, 131 had CIN1, 37 had CIN2/3, and nine had carcinoma. The immediate rates of CIN2 + lesions and CIN3 + lesions in patients who were not HR-HPV16/18-positive were comparable to those in patients who were HPV16/18-positive (P = 0.699). In addition, among patients diagnosed with CIN2 + lesions, 8 (17.39%) patients were women aged < 30 years. When pathological results were used as a reference, the consistency rate of colposcopy was 61.0% (227/372). Multivariate analyses revealed that age and the type of cervical transformation zone were independent factors affecting the accuracy of colposcopy (P < 0.001).
CONCLUSIONS: In countries with limited resources, immediate colposcopy referral should be recommended for patients who are cytology negative but HR-HPV-positive (including non-16/18 HR-HPV-positive), and cervical cancer screening via cotesting should be suggested for women aged < 30 years. Colposcopy has moderate diagnostic value and can be affected by age and the type of cervical transformation zone.
PG negative （pepsinogen（PG）Ⅰ \> 70ng/ml or PGⅠ/PGⅡ \>7.0）and Hp (helicobacter pylori) negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
The present invention relates to the use of and method for using MnO nanoparticles as MRI T1 contrasting agents which reduces T1 of tissue. More specifically, the present invention is directed to MRI T1 contrasting agent comprising MnO nanoparticle coated with a biocompatible material bound to a biologically active material such as a targeting agent, for example tumor marker etc., and methods for diagnosis and treatment of tumor etc. using said MRI T1 contrasting agent, thereby obtaining more detailed images than the conventional MRI T1-weighted images. The MRI T1 contrasting agent of the present invention allows a high resolution anatomic imaging by emphasizing T1 contrast images between tissues based on the difference of accumulation of the contrasting agent in tissues. Also, the MRI T1 contrasting agent of the present invention enables to visualize cellular distribution due to its high intracellular uptake. The MRI T1 contrasting agent of the present invention can be used for target-specific diagnosis and treatment of various diseases such as tumor etc. when targeting agents binding to disease-specific biomarkers are conjugated to the surface of nanoparticles.
Retinal ischemia-reperfusion (IR) injury is a basic pathological procedure in clinic and associated with various ischemic retinal diseases, including glaucoma, diabetic retinopathy, retinal vascular occlusion, etc. The purpose of this work is to investigate the effect of ciclopirox olamine (CPX) on retinal IR injury and further explore the underlying mechanism. In vitro assay exhibited that CPX exhibited significant neuroprotection against oxygen glucose deprivation (OGD) and oxidative stress-induced injuries in 661W photoreceptor cells. OGD injury showed a proinflammatory phenotype characterized by significantly increased production of cytokines (IL-6, IL-23 and TNF-α), while CPX significantly inhibited their secretion. In addition, the in vivo experiment demonstrated that CPX significantly preserved the normal thickness of the retina. Therefore, we suggest that CPX is identified in our research as a prospective therapeutic agent for retinal IR injury.
Patients with mammographically newly detected ductal in situ carcinoma who undergo surgery at CHC Rijeka in 2024, 2025, and 2026 (consecutively), who agree to have a CEM performed prior to surgery as part of the diagnostic work-up in addition to standard mammography, and who agree to participate in the examination. Group number: 50 patients.
Treatment C. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
A dosimeter has separate phosphors (9,10) for simultaneoulsy measuring eye and skin doses. The skin phosphor overlies the eye phosphor and acts as part of the filter for radiation reaching the eye phosphor. The phosphors may be removably located in recesses (4,5) on opposite sides of a plate (1) having an opaque openable cover (2,3) on each side to hold the phosphors in place. The base (13) of the recesses acts as a further part of the filter for radiation to the eye phosphor, and the cover over the skin phosphor includes a hole covered by a thin opaque sheet (12) to filter radiation. The covers are pref. hinged to opposite edges of the plate, and the plate, hinges and covers are formed as an integral assembly from opaque plastics, e.g. carbon-filled polypropylene.
The safety and efficacy of eplerenone have been evaluated alone and in combination with other antihypertensive agents in clinical studies of 3091 hypertensive patients. The studies included 46% women, 14% Blacks, and 22% elderly (age ≥65). The studies excluded patients with elevated baseline serum potassium (>5.0 mEq/L) and elevated baseline serum creatinine (generally >1.5 mg/dL in males and >1.3 mg/dL in females).

Two fixed-dose, placebo-controlled, 8- to 12-week monotherapy studies in patients with baseline diastolic blood pressures of 95 to 114 mm Hg were conducted to assess the antihypertensive effect of eplerenone. In these two studies, 611 patients were randomized to eplerenone and 140 patients to placebo. Patients received eplerenone in doses of 25 mg to 400 mg daily as either a single daily dose or divided into two daily doses. The mean placebo-subtracted reductions in trough cuff blood pressure achieved by eplerenone in these studies at doses up to 200 mg are shown in Figures 3 and 4.

Patients treated with eplerenone 50 mg to 200 mg daily experienced significant decreases in sitting systolic and diastolic blood pressure at trough with differences from placebo of 6–13 mm Hg (systolic) and 3–7 mm Hg (diastolic). These effects were confirmed by assessments with 24-hour ambulatory blood pressure monitoring (ABPM). In these studies, assessments of 24-hour ABPM data demonstrated that eplerenone, administered once or twice daily, maintained antihypertensive efficacy over the entire dosing interval. However, at a total daily dose of 100 mg, eplerenone administered as 50 mg twice per day produced greater trough cuff (4/3 mm Hg) and ABPM (2/1 mm Hg) blood pressure reductions than 100 mg given once daily.

Blood pressure lowering was apparent within 2 weeks from the start of therapy with eplerenone, with maximal antihypertensive effects achieved within 4 weeks. Stopping eplerenone following treatment for 8 to 24 weeks in six studies did not lead to adverse event rates in the week following withdrawal of eplerenone greater than following placebo or active control withdrawal. Blood pressures in patients not taking other antihypertensives rose 1 week after withdrawal of eplerenone by about 6/3 mm Hg, suggesting that the antihypertensive effect of eplerenone was maintained through 8 to 24 weeks.

Blood pressure reductions with eplerenone in the two fixed-dose monotherapy studies and other studies using titrated doses, as well as concomitant treatments, were not significantly different when analyzed by age, gender, or race with one exception. In a study in patients with low renin hypertension, blood pressure reductions in Blacks were smaller than those in whites during the initial titration period with eplerenone.

Eplerenone has been studied concomitantly with treatment with ACE inhibitors, ARB, calcium channel blockers, beta-blockers, and hydrochlorothiazide. When administered concomitantly with one of these drugs eplerenone usually produced its expected antihypertensive effects.
The therapist straddled that leg, and raised the other leg by placing the heel on the shoulder. The therapist then flexed the participant's hip, maintaining knee extension, to the point of discomfort indicated by the patient or the therapist's perceived end of range. In this position the leg was held straight for 10 seconds and immediately afterwards the participant was asked to perform a maximum isometric contraction for 5 seconds using the therapist's shoulder as counter resistance, thus keeping the leg straight at the same point. As soon as the contraction stops, the therapist flexes the hip again until a new range limit is reached, repeating the same protocol again. The total duration is 60 seconds, consisting of 4 passive stretches of 10 seconds each and 4 isometric contractions against resistance of 5 seconds each.
The invention provides a hydrophobization polysaccharide and a preparation method and application thereof. The general structural formula of the hydrophobized polysaccharide is G-P-O; wherein G is polysaccharide or disaccharide, P is a connecting molecule with carboxyl at two ends formed by condensing amino acid and diacid, and O is cholesterol; g and P are connected with hydroxyl on the polysaccharide or disaccharide through ester bonds, and P and O are connected through ester bonds. The hydrophobic polysaccharide has immunoregulation performance, and can play a role in immunoregulation together with the bupleurum extract. The raw materials for synthesizing the hydrophobic polysaccharide are safe and nontoxic, and can be used in the fields of food and medicines. The hydrophobic polysaccharide is nontoxic, can be completely decomposed in nature, and has no toxicity. The hydrophobic polysaccharide modifier belongs to a novel high-efficiency drug delivery carrier, the prepared liquid medicine has high pharmacological activity, is stronger than the existing drug delivery system, and has obvious pharmacological action when being a trace amount of liquid medicine, and has the characteristic of one-time cure without relapse due to belonging to an immunoregulatory drug.
Subjects will be randomized to receive single dose of 4 mg daprodustat in fed state during Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fasted state. There will be a wash-out period of 5 days between the Periods.
A method and system of facilitating communication within a healthcare environment is disclosed. The healthcare environment has a directory of providers and a patient census system having patients and patient events. The method and system include a database server configured and arranged to receive and store patients and patient events from the patient census system and providers from the directory, the providers automatically mapped to patients based on predetermined criteria. Patient events are recorded in the patient census system and automatically pushed to the providers mapped to the respective patient in real-time. Preferably, the patient events are pushed to mobile device carried by providers, wirelessly and in real-time. Providers may manage, create and assign patient events via the mobile device, which assigned providers receive and may act on or complete.
PURPOSE: A natural antibacterial composition and a feminine cleanser composition are provided to ensure excellent antibacterial and antifungal effect and to prevent and treat vaginitis. CONSTITUTION: An antibacterial composition contains 70-100 wt% of natural crude drug extract. The natural crude drug extract contains 1.0-4.0 of Sohora roots, 20-40 of Salvia Miltiorrhiza roots, 1.0-4.0 of Cnidium monieri(L). Cuss, 1.0-4.0 of Kochiae fructus, 40-60 of Scutellaria roots, 5.0-15 of Coptidis Rhizoma, and 1.0-4.0 of Phellodendron bark. The extract is prepared by purified water, ethyl acetate, butyl acetate, methyl alcohol, propanol, isopropyl alchol, or butyl alcohol. A feminine cleanser composition contains 1-20 wt% of antibacterial composition.
People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
The present invention relates to a process for the manufacture of a preparation containing specific antibodies against the K-99 antigen of various strains of enterotoxigenic Escherichia coli (etec). In said process the milk obtained from postpartum cows, which had been previously vaccinated with E. coli strain 168, is clotted with a suitable enzyme. The fatty serum is then separated from the cheese obtained, the fat is then separated out, the fat-free serum is then subjected to ultrafiltration through a suitable number of appropriate membranes so that 30-50% of the water present is removed the retentate is then sterilized. Suitable membranes are those which are permeable only to molecules of less than about 22,000-30,000 daltons molecular weight. The preparation is advantageously lyophilized and the lyophilized preparation is subsequently sterilized by irridation, e.g. with Co60.
INTRODUCTION: The variety of robotic surgery systems, training modalities, and assessment tools within robotic surgery training is extensive. This systematic review aimed to comprehensively overview different training modalities and assessment methods for teaching and assessing surgical skills in robotic surgery, with a specific focus on comparing objective and subjective assessment methods.
METHODS: A systematic review was conducted following the PRISMA guidelines. The electronic databases Pubmed, EMBASE, and Cochrane were searched from inception until February 1, 2022. Included studies consisted of robotic-assisted surgery training (e.g., box training, virtual reality training, cadaver training and animal tissue training) with an assessment method (objective or subjective), such as assessment forms, virtual reality scores, peer-to-peer feedback or time recording.
RESULTS: The search identified 1591 studies. After abstract screening and full-texts examination, 209 studies were identified that focused on robotic surgery training and included an assessment tool. The majority of the studies utilized the da Vinci Surgical System, with dry lab training being the most common approach, followed by the da Vinci Surgical Skills Simulator. The most frequently used assessment methods included simulator scoring system (e.g., dVSS score), and assessment forms (e.g., GEARS and OSATS).
CONCLUSION: This systematic review provides an overview of training modalities and assessment methods in robotic-assisted surgery. Dry lab training on the da Vinci Surgical System and training on the da Vinci Skills Simulator are the predominant approaches. However, focused training on tissue handling, manipulation, and force interaction is lacking, despite the absence of haptic feedback. Future research should focus on developing universal objective assessment and feedback methods to address these limitations as the field continues to evolve.
PROBLEM TO BE SOLVED: To obtain a skin external agent, enabling the synergistic enhancement of hyaluronidase activity-inhibiting effect and tyrosinase activity-inhibiting effect and excellent in stability and safety by compounding an extract of Melissa officinalis with an antiinflammatory agent. SOLUTION: This skin external agent contains an extract of Melissa officinalis of a plant belonging to the family Labiatae and an antiinflammatory agent (e.g. glycyrrhizic acid) each in an amount of 0.001-3wt.% as active components. The agent can be formulated into a lotion, an oil solution, a cream, an ointment, etc., and prepared as a cosmetic such as a skin lotion, a cream, an emulsified lotion, a pack, a beauty lotion or a cleansing agent. The skin external agent can keep smoothness and softness of the skin, excellent in the preventing effect on the occurrence of fine wrinkles and dryness of the skin and good in beautifying effect. The extract of Melissa officinalis is obtained by extracting a total plant, leaves, stems, roots, seeds or flowers of Melissa officinalis singly or in combination, using an organic solvent, etc.